Intravitreal Injection of Conbercept Combined with Ahemd Glaucoma Valve Implants and Panretinal Photocoagulation Treatment for Neovascular Glaucoma

Abstract

Objective: To observe the clinical effects of intravitreal injection of conbercept combined with Ahemd glaucoma valve implant and panretinal photocoagulation treatment for neovascular glaucoma (NVG). Methods: In this retrospective case series study, 16 NVG patients (17 eyes), at the Number 986 Hospital of the Air Force, were treated from June, 2017 to June, 2018 with intravitreal injection of conbercept combined with Ahemd glaucoma valve implants and panretinal photocoagulation. The disappearance of neovascularization, intraocular pressure (IOP) and best corrected visual acuity (BCVA) were compared between preoperative and postoperative conditions. The data were analyzed by repeated measures ANOVA. The IOP between preoperative and every follow-up was analyzed with independent sample t test. Results: After injection, neovascularization was greatly diminshed by 3 d, and completely vanished by 1 month. The preoperative IOP was 43.3±7.6 mmHg, and postoperative IOP was 14.8±4.8 mmHg, 13.7±3.9 mmHg, 14.5±4.6 mmHg, 13.6±5.4 mmHg and 13.9±4.6 mmHg at 3 d, 7 d, 1 month, 3 months, and 6 months, respectively. There were no significant differences in IOP at different postoperative time points (F=9.58, P=0.006). Compared with preoperative levels, there were significant differences at every follow-up (P<0.05). Compared with preoperative measurements, the BCVA of 5 eyes improved. Conclusions: Intravitreal injection of conbercept combined with Ahemd glaucoma valve implants and panretinal photocoagulation is a safe and effective treatment for neovascular glaucoma. Key words: neovascular glaucoma; conbercept; Ahemd glaucoma valve; panretinal photocoagulation; intravitreal injection